EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Complement activation profiles in anti‐acetylcholine receptor positive myasthenia gravis

Frauke Stascheit iD, Omar Chuquisana, Christian W Keller iD, Philip Alexander Ambrose, Sarah Hoffmann, Catharina C Gross, Sophie Lehnerer, Heinz Wiendl, Nick Willcox, Andreas Meisel iD, Jan D Lünemann iD

European Journal of Neurology · 2023-05 · 30 (5) · 1409-1416

DOI: 10.1111/ene.15730 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 24.02.2023. Verfasst von Frauke Stascheit und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology with Experimental Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Autoantibodies, Complement Activation, Myasthenia Gravis, Receptors, Cholinergic. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Complement component 5 (C5) targeting therapies are clinically beneficial in patients with acetylcholine receptor antibody + (AChR‐Ab + ) generalized myasthenia gravis (MG). That clearly implicates antibody‐mediated complement activation in MG pathogenesis. Here, classical and alternative complement pathways were profiled in patients from different MG subgroups.

Methods

In a case–control study, concentrations of C3a, C5a and sC5b9 were simultaneously quantified, indicating general activation of the complement system, whether via the classical and lectin pathways (C4a) or the alternative pathway (factors Ba and Bb) in MG patients with AChR or muscle‐specific kinase antibodies (MuSK‐Abs) or seronegative MG compared to healthy donors.

Results

Treatment‐naïve patients with AChR‐Ab + MG showed substantially increased plasma levels of cleaved complement components, indicating activation of the classical and alternative as well as the terminal complement pathways. These increases were still present in a validation cohort of AChR‐Ab + patients under standard immunosuppressive therapies; notably, they were not evident in patients with MuSK‐Abs or seronegative MG. Neither clinical severity parameters (at the time of sampling or 1 year later) nor anti‐AChR titres correlated significantly with activated complement levels.

Conclusions

Markers indicative of complement activation are prominently increased in patients with AChR‐Ab MG despite standard immunosuppressive therapies. Complement inhibition proximal to C5 cleavage should be explored for its potential therapeutic benefits in AChR‐Ab + MG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesComplement ActivationMyasthenia GravisReceptors, CholinergicHumansCase-Control StudiesComplement System ProteinsComplement Pathway, AlternativeComplement Pathway, ClassicalMaleFemaleYoung AdultAdultMiddle Aged

Stichwörter der Autor:innen

acetylcholine receptorantibodiesbiomarkercomplement activationmyasthenia gravis

Substanzen

AutoantibodiesComplement System ProteinsReceptors, Cholinergic

Autor:innen und Institutionen

  • Department of Neurology with Experimental Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
  • Department of Clinical Neurology, University of Nottingham, Queen's Medical Centre, Nottingham, UK.
  • Department of Clinical Neurosciences, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Center for Stroke Research Berlin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

ORCID-Profile: Frauke Stascheit, Christian W Keller, Andreas Meisel, Jan D Lünemann

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Stascheit, F., Chuquisana, O., Keller, C. W., Ambrose, P. A., Hoffmann, S., Gross, C. C., Lehnerer, S., Wiendl, H., Willcox, N., Meisel, A., & Lünemann, J. D. (2023). Complement activation profiles in anti‐acetylcholine receptor positive myasthenia gravis. European Journal of Neurology, 30(5), 1409-1416. https://doi.org/10.1111/ene.15730

Vancouver

Stascheit F, Chuquisana O, Keller CW, Ambrose PA, Hoffmann S, Gross CC, et al. Complement activation profiles in anti‐acetylcholine receptor positive myasthenia gravis. European Journal of Neurology. 2023;30(5):1409-1416. doi:10.1111/ene.15730

BibTeX
@article{Stascheit2023,
  author = {Stascheit, Frauke and Chuquisana, Omar and Keller, Christian W and Ambrose, Philip Alexander and Hoffmann, Sarah and Gross, Catharina C and Lehnerer, Sophie and Wiendl, Heinz and Willcox, Nick and Meisel, Andreas and Lünemann, Jan D},
  title = {Complement activation profiles in anti‐acetylcholine receptor positive myasthenia gravis},
  journal = {European Journal of Neurology},
  year = {2023},
  volume = {30},
  number = {5},
  pages = {1409--1416},
  doi = {10.1111/ene.15730}
}
Kostenlos starten →